Celebrex, Bextra Stabilizing After FDA Advisory Committee Review, Pfizer Says

Company is predicting a return to growth in the COX-2 category once FDA completes work on new labeling. Celebrex and Bextra "will remain critical treatment options for many years to come," Pfizer tells analysts.